Kleanthis G. Xanthopoulos, Ph.D., CEO of Anadys, to Join Enterprise Partners as a Managing Director by Year-End
Thursday June 15, 7:30 am ET
- E&Y Entrepreneur of the Year will focus on Innovation in Biopharmaceuticals -
SAN DIEGO, June 15-- Enterprise Partners Venture Capital, a leading Southern California venture capital firm focusing on the life sciences and technology, announced today that Kleanthis G. Xanthopoulos, Ph.D., will join the firm by year-end as a Managing Director, after completing his transition from Anadys Pharmaceuticals,(NASDAQ Stock Symbol ANDS) a biopharmaceutical company he founded in 2000 and where he currently serves as President and Chief Executive Officer. He will remain on the Anadys Board of Directors.
Dr. Xanthopoulos was voted the 2006 Ernst & Young Entrepreneur of the Year at the annual award ceremony June 14 in San Diego.
Dr. Xanthopoulos said, "I could not be more proud of the groundbreaking work our team at Anadys has done in developing small-molecule drugs for the treatment of hepatitis, other serious viral infections and cancer. The experience of building a successful company has been a transformative one for me, and I look forward to the opportunities Enterprise affords and to working with entrepreneurs in a broad range of the life sciences."
At Enterprise, Kleanthis will join Managing Directors Bob Conn, Carl Eibl, Drew Senyei and Bill Stensrud, along with Partner Emeritus Jim Berglund. The firm will continue investing in a balanced portfolio of technology and life sciences, with Dr. Xanthopoulos focusing initially on the expanding field of biopharmaceuticals. He joins the existing life sciences practice at Enterprise that includes Drew Senyei, M.D., and Entrepreneurs-in-Residence Krisztina Zsebo, Ph.D. and Steven Brauer.
Drew Senyei, M.D., Managing Director and head of the life sciences practice at Enterprise, said, "Kleanthis is a truly accomplished company builder and entrepreneur having led Anadys through a successful IPO and negotiating a landmark deal with Novartis worth up to $570M to develop, manufacture and commercialize drugs for chronic hepatitis C virus (HCV), hepatitis B virus (HBV) and other infections. This partnership is the largest in the history of biotech for a Phase I compound. The Novartis deal was not only unprecedented in its creativity, but it also signaled that large pharmaceutical companies are now prepared to make significant investments in Phase I compounds. Kleanthis has personally experienced the challenges and rewards of transforming good science into good business. We welcome the operating experience, the entrepreneurial creativity, and the intellectual rigor Kleanthis brings to Enterprise."
Dr. Xanthopoulos is the Founder of Anadys Pharmaceuticals and has served as President, Chief Executive Officer and as a Director since May 2000. From 1997 to 2000 he held a variety of positions at Aurora Biosciences Corporation, including Vice President, Genomics & Molecular Biology. Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at The National Institutes of Health. He was a Postdoctoral Research Fellow at the Rockefeller University in New York from 1987 to 1990 and an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Sweden from 1991 to 1995. Dr. Xanthopoulos is also a member of the Board of Directors of Odyssey Thera, Inc. and Executive Board Member of BIOCOM, Southern California's life science industry association.
An Onassis Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
About Enterprise Partners Venture Capital
Enterprise Partners was founded in 1985 and is the largest venture firm headquartered in Southern California, with over $1.1 billion in capital under management. Enterprise focuses on seed, early stage and promising later stage companies across a broad spectrum of technologies and the life sciences. The firm is currently investing its sixth fund and is headquartered in San Diego.
Thursday June 15, 7:30 am ET
- E&Y Entrepreneur of the Year will focus on Innovation in Biopharmaceuticals -
SAN DIEGO, June 15-- Enterprise Partners Venture Capital, a leading Southern California venture capital firm focusing on the life sciences and technology, announced today that Kleanthis G. Xanthopoulos, Ph.D., will join the firm by year-end as a Managing Director, after completing his transition from Anadys Pharmaceuticals,(NASDAQ Stock Symbol ANDS) a biopharmaceutical company he founded in 2000 and where he currently serves as President and Chief Executive Officer. He will remain on the Anadys Board of Directors.
Dr. Xanthopoulos was voted the 2006 Ernst & Young Entrepreneur of the Year at the annual award ceremony June 14 in San Diego.
Dr. Xanthopoulos said, "I could not be more proud of the groundbreaking work our team at Anadys has done in developing small-molecule drugs for the treatment of hepatitis, other serious viral infections and cancer. The experience of building a successful company has been a transformative one for me, and I look forward to the opportunities Enterprise affords and to working with entrepreneurs in a broad range of the life sciences."
At Enterprise, Kleanthis will join Managing Directors Bob Conn, Carl Eibl, Drew Senyei and Bill Stensrud, along with Partner Emeritus Jim Berglund. The firm will continue investing in a balanced portfolio of technology and life sciences, with Dr. Xanthopoulos focusing initially on the expanding field of biopharmaceuticals. He joins the existing life sciences practice at Enterprise that includes Drew Senyei, M.D., and Entrepreneurs-in-Residence Krisztina Zsebo, Ph.D. and Steven Brauer.
Drew Senyei, M.D., Managing Director and head of the life sciences practice at Enterprise, said, "Kleanthis is a truly accomplished company builder and entrepreneur having led Anadys through a successful IPO and negotiating a landmark deal with Novartis worth up to $570M to develop, manufacture and commercialize drugs for chronic hepatitis C virus (HCV), hepatitis B virus (HBV) and other infections. This partnership is the largest in the history of biotech for a Phase I compound. The Novartis deal was not only unprecedented in its creativity, but it also signaled that large pharmaceutical companies are now prepared to make significant investments in Phase I compounds. Kleanthis has personally experienced the challenges and rewards of transforming good science into good business. We welcome the operating experience, the entrepreneurial creativity, and the intellectual rigor Kleanthis brings to Enterprise."
Dr. Xanthopoulos is the Founder of Anadys Pharmaceuticals and has served as President, Chief Executive Officer and as a Director since May 2000. From 1997 to 2000 he held a variety of positions at Aurora Biosciences Corporation, including Vice President, Genomics & Molecular Biology. Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at The National Institutes of Health. He was a Postdoctoral Research Fellow at the Rockefeller University in New York from 1987 to 1990 and an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Sweden from 1991 to 1995. Dr. Xanthopoulos is also a member of the Board of Directors of Odyssey Thera, Inc. and Executive Board Member of BIOCOM, Southern California's life science industry association.
An Onassis Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.
About Enterprise Partners Venture Capital
Enterprise Partners was founded in 1985 and is the largest venture firm headquartered in Southern California, with over $1.1 billion in capital under management. Enterprise focuses on seed, early stage and promising later stage companies across a broad spectrum of technologies and the life sciences. The firm is currently investing its sixth fund and is headquartered in San Diego.
posted by doublezero at
8:33 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home